Tasty Topics: Addressing the potential impact of the BIOSECURE Act

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:

• Tom Willson, Vice President of Contract Manufacturing at Pfizer CentreOne
• Hanna Lesch, Chief Technology Officer at Exothera 
• Stephen Grant, entrepreneurial advisor and angel investor

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tom, Hanna, and Stephen, covering:

• Unraveling the potential seismic shift in the pharmaceutical outsourcing industry; the BIOSECURE Act and its implications
• Will the BIOSECURE Act accelerate a trend toward a more regionalized approach to drug development and manufacturing?
• How Biotechs/CDMOs are going to adapt their strategies post BIOSECURE Act
• What impacts BIOSECURE will have on the supply chain 

 

The BIOSECURE Act has the potential to significantly restrict the ability of biotechnology companies to collaborate with certain Chinese companies without losing the ability to contract with the US government. Our guests provide insightful perspectives on the potential implications of this legislation on the supply chain of life-saving drugs across America.

 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

 

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.